Is ANI Pharmaceuticals (ANIP) Pricing Reflect Its Strong Multi Year Share Price Performance?
- If you are wondering whether ANI Pharmaceuticals at around US$78.64 is priced attractively or already reflects a lot of optimism, the starting point is to understand what the current share price implies about future expectations.
- The stock shows mixed recent returns, with a 2.8% decline over 7 days, a 6.2% gain over 30 days, a 0.3% return year to date, 12.6% over 1 year, 108.5% over 3 years and 136.3% over 5 years.
- Recent coverage around ANI Pharmaceuticals has focused on its position within the US pharmaceuticals and biotech space and how investors are weighing potential opportunities against sector specific risks. This context helps explain why the share price has moved in bursts rather than in a straight line, as sentiment reacts to both company specific updates and broader industry news.
- On Simply Wall St, ANI Pharmaceuticals currently has a value score of 3 out of 6, based on a set of six valuation checks that each test for signs of the shares being undervalued. The sections ahead will unpack the standard valuation methods behind that score before finishing with a way to assess value that goes beyond just the headline metrics.
Find out why ANI Pharmaceuticals's 12.6% return over the last year is lagging behind its peers.
Approach 1: ANI Pharmaceuticals Discounted Cash Flow (DCF) Analysis
A Discounted Cash Flow, or DCF, model takes estimates of the cash a company could generate in the future and discounts those back to what they might be worth today. It is a way of asking what a stream of projected cash flows could be worth in a single number right now.
For ANI Pharmaceuticals, the latest trailing twelve month Free Cash Flow is about $154.16 million. Using a 2 Stage Free Cash Flow to Equity model, analysts and Simply Wall St projections extend out to 2035, with a specific forecast of $221.77 million in Free Cash Flow for 2027. Estimates beyond the usual analyst window are extrapolated by Simply Wall St rather than based on explicit broker forecasts.
Running these projections through the DCF model results in an estimated intrinsic value of about $367.14 per share. Compared with the recent share price of roughly $78.64, the model points to an implied discount of 78.6%, which suggests the shares screen as significantly undervalued on this metric alone.
Result: UNDERVALUED
Our Discounted Cash Flow (DCF) analysis suggests ANI Pharmaceuticals is undervalued by 78.6%. Track this in your watchlist or portfolio, or discover 56 more high quality undervalued stocks.
Approach 2: ANI Pharmaceuticals Price vs Earnings
P/E is a common way to value profitable companies because it links what you pay per share to the earnings that support that share price. It gives you a quick sense of how many years of current earnings the market is willing to pay for.
What counts as a “normal” P/E depends on how investors see growth potential and risk. Higher expected growth or lower perceived risk can justify a higher P/E, while slower growth or higher risk usually comes with a lower one.
ANI Pharmaceuticals currently trades on a P/E of about 25.5x. That is above the Pharmaceuticals industry average of roughly 15.9x and also above the selected peer group average of around 13.8x. Simply Wall St’s Fair Ratio for ANI Pharmaceuticals is 18.2x, which is a proprietary estimate of what the P/E might be based on factors such as earnings growth, industry, profit margins, market value and company specific risks.
The Fair Ratio is more tailored than a simple peer or industry comparison because it adjusts for ANI Pharmaceuticals own characteristics rather than assuming it should trade in line with a broad group. Comparing the current P/E of 25.5x with the Fair Ratio of 18.2x suggests the shares look expensive on this metric.
Result: OVERVALUED
P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 19 top founder-led companies.
Upgrade Your Decision Making: Choose your ANI Pharmaceuticals Narrative
Earlier it was mentioned that there is an even better way to understand valuation. This is where Narratives come in, giving you a simple way to connect your view of ANI Pharmaceuticals with concrete numbers such as fair value, revenue, earnings and margins, and then compare that view with the current share price.
A Narrative is your story about the company, written in financial terms. You decide what you think is reasonable for ANI Pharmaceuticals future growth, profitability and risk, and the platform turns that into a forecast and a fair value estimate.
On Simply Wall St, Narratives sit inside the Community page and are designed to be easy to use. You can pick or adjust assumptions rather than build a spreadsheet, then see in one place how your fair value stacks up against the latest market price to help you decide if the stock looks expensive or cheap on your terms.
Because Narratives update when new information arrives, such as earnings reports or product news, you might, for example, align with a more cautious ANI view that anchors on a US$90.00 fair value, or with a more optimistic view closer to US$120.00, and see instantly how each storyline changes the gap between price and value as conditions evolve.
Do you think there's more to the story for ANI Pharmaceuticals? Head over to our Community to see what others are saying!
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com